
News|Articles|February 13, 2019
Tegsedi for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Author(s)Drew Boxler
Advertisement
Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
- Platelet count less than 100 x 109/L (4, 5.1)
- History of acute glomerulonephritis caused by TEGSEDI
- Patients with a history of a hypersensitivity reaction to TEGSEDI
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
3
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
4
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
5







































